males (84.7% versus 63.5%) and the mean baseline noninflammatory lesion count was a little higher than that noted in the adult males (45.5 versus 39.8), although the proportion of subjects classified as severe (EGSS=4) was slightly lower in the adolescent male population (11.5% versus 12.9%). In the overall study populations, efficacy of tazarotene 0.045% lotion in Caucasian or Black subjects was similar, so it is unlikely that these differences would have influenced efficacy in the two male populations.
Evaluator’s Global Severity Score (EGSS) Significantly more adult male subjects achieved at least a 2-grade improvement in EGSS with tazarotene 0.045% lotion compared with adolescent male subjects at week 12 (42.1% versus 24.6%, P=0.006); see Figure 1. Differences were significant from week 8. In addition, 33.0% of adult males were considered ‘treatment successes’ (defined as at least a 2-grade improvement in EGSS and ‘clear’ or ‘almost clear’) compared with 21.6% of adolescent subjects treated with tazarotene 0.045% lotion (P=0.059).
Tazarotene 0.045% lotion was more effective in achieving an absolute reduction in lesion counts in adult males. At week 12, the absolute reduction in inflammatory and noninflammatory lesion count relative to baseline for the adult male group was